Multinational Association of Supportive Care in Cancer (MASCC) 2020 Clinical Practice Recommendations for the Management of Immune-mediated Adverse Events from Checkpoint Inhibitors

Articles (7 in this collection)

1. MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors

   Authors (first, second and last of 4)

   • Bernardo L. Rapoport
   • Ronald Anderson
   • Douglas B. Johnson

   • Content type: Editorial
   • Published: 04 September 2020

   • Pages: 6107 - 6110

2. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity

   Authors (first, second and last of 13)

   • Vickie R. Shannon
   • Ronald Anderson
   • Bernardo L. Rapoport

   • Content type: Special Article
   • Published: 03 September 2020

   • Pages: 6145 - 6157

   

3. Cancer immunotherapy–related adverse events: causes and challenges

   Authors (first, second and last of 13)

   • Ada G. Blidner
   • Jennifer Choi
   • Ronald Anderson

   • Content type: Special Article
   • Published: 28 August 2020

   • Pages: 6111 - 6117

4. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities

   Authors (first, second and last of 14)

   • Tim Cooksley
   • Monica Girotra
   • Bernardo L. Rapoport

   • Content type: Special Article
   • Published: 27 August 2020

   • Pages: 6175 - 6181

   

5. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors

   Authors (first, second and last of 13)

   • Michael Dougan
   • Ada G. Blidner
   • Bernardo L. Rapoport

   • Content type: Special Article
   • Published: 27 August 2020

   • Pages: 6129 - 6143

6. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

   Authors (first, second and last of 15)

   • Maria E. Suarez-Almazor
   • Xerxes Pundole
   • Bernardo L. Rapoport

   • Content type: Special Article
   • Published: 27 August 2020

   • Pages: 6159 - 6173

   

7. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

   Authors (first, second and last of 14)

   • Jennifer Choi
   • Ronald Anderson
   • Mario E. Lacouture

   • Content type: Special Article
   • Published: 27 August 2020

   • Pages: 6119 - 6128